CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...
CervoMed: Neflamapimod Phase 2b Trial In Dementia With Lewy Bodies Patients Fails To Meet Targets
CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...
Finanznachrichten5h
CervoMed Inc.: CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant designed to inhibit p38 mitogen-activated protein kinase alpha. Neflamapimod ...
CervoMed's dementia drug fails mid-stage trial, shares slump
CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b ...
CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
CervoMed price target lowered to $4 from $45 at Roth MKM
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...
Outsourcing-pharma14d
FDA grants orphan drug designation to CervoMed’s dementia drug
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational ...
CervoMed Shares Slide to All-Time Low After Study Failure
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
Boston-based CervoMed (CRVO) said the Phase 2b trial of its neflamapimod did not meet significant statistical thresholds for its primary endpoint of a change in the Clinical Dementia Rating Sum of ...
FierceBiotech2d
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...
Morningstar15d
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
“We are pleased to have received Orphan Drug Designation as it implicitly recognizes the scientific rationale and potential for neflamapimod to treat this debilitating condition. Patients ...